Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-08-13 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2019-08-13 English
We are enclosing herewith copy of the transcript of the Company''s Q1 FY 20 earnings conference call dated 7 August 2019. The transcript is also available on the Company''s website ....
Regulatory Filings
2019-08-13 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is titled as an extract of consolidated unaudited financial results for the quarter ended 30th June 2019. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs quarterly financial disclosures. The document contains detailed financial data including revenue, profit before and after tax, earnings per share, and notes on accounting standards and audit review. The length is 7333 characters, which is sufficient to contain substantive financial data. The document is not a full annual report but a quarterly financial report with actual financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2019-08-07 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached letter dated 07th August, 2019.
Interim / Quarterly Report Classification · 95% confidence The document is titled as an extract of consolidated unaudited financial results for the quarter ended 30th June 2019. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results disclosures. The document contains detailed financial data for the quarter, including revenue, profit before and after tax, earnings per share, and notes on accounting standards and audit review. It is not a full annual report but a quarterly financial report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is over 5,000 characters and contains actual financial statements, not just an announcement or certification, so it is not an RPA or RNS. Hence, the correct classification is IR with high confidence.
2019-08-07 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a short notice dated 7th August 2019 from Cipla Limited addressed to stock exchanges and the Luxembourg stock exchange. It informs about the outcome of a Board meeting where the unaudited financial results for the quarter ended 30th June 2019 were approved. The document references Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relate to disclosure of financial results. The document is brief (1320 characters) and does not contain the actual financial statements or detailed financial data, only an announcement that the Board approved the unaudited quarterly results. Therefore, it is not the Interim/Quarterly Report itself but an announcement of the outcome of the Board meeting approving those results. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure, not a full report or earnings release.
2019-08-07 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached letter dated 07th August, 2019
Regulatory Filings Classification · 95% confidence The document is a short notice dated 7th August 2019 from Cipla Limited addressed to stock exchanges and the Luxembourg stock exchange. It references the outcome of a Board meeting where the unaudited financial results for the quarter ended 30th June 2019 were approved. The document is brief (1320 characters) and serves as an announcement of the Board meeting outcome and approval of quarterly financial results, not the full financial report itself. It does not contain detailed financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about the Board meeting outcome and financial results approval, rather than the full Interim/Quarterly Report (IR).
2019-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.